Pramod K Srivastava
Overview
Explore the profile of Pramod K Srivastava including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
2244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singhaviranon S, Dempsey J, Hagymasi A, Mandoiu I, Srivastava P
Nat Immunol
. 2025 Jan;
26(2):240-251.
PMID: 39789375
T cells recognize neoepitope peptide-major histocompatibility complex class I on cancer cells. The strength (or avidity) of the T cell receptor-peptide-major histocompatibility complex class I interaction is a critical variable...
2.
Al-Okaily A, Abu Khashabeh R, Alsmadi O, Ahmad Y, Sultan I, Tbakhi A, et al.
J Immunol Methods
. 2024 Jun;
531:113713.
PMID: 38925438
MHC class I pathway consists of four main steps: proteasomal cleavage in the cytosol in which precursor proteins are cleaved into smaller peptides, which are then transported into the endoplasmic...
3.
Srivastava P
J Clin Invest
. 2024 Mar;
134(5).
PMID: 38426497
A proportion of somatic mutations in tumors create neoepitopes that can prime T cell responses that target the MHC I-neoepitope complexes on tumor cells, mediating tumor control or rejection. Despite...
4.
Structural and physical features that distinguish tumor-controlling from inactive cancer neoepitopes
Custodio J, Ayres C, Rosales T, Brambley C, Arbuiso A, Landau L, et al.
Proc Natl Acad Sci U S A
. 2023 Dec;
120(51):e2312057120.
PMID: 38085776
Neoepitopes arising from amino acid substitutions due to single nucleotide polymorphisms are targets of T cell immune responses to cancer and are of significant interest in the development of cancer...
5.
Gillig M, Brennick C, George M, Balsbaugh J, Shcheglova T, Mandoiu I, et al.
J Immunol
. 2023 Nov;
211(12):1783-1791.
PMID: 37966257
Identification of neoepitopes that can control tumor growth in vivo remains a challenge even 10 y after the first genomics-defined cancer neoepitopes were identified. In this study, we identify a...
6.
Si Y, Wang Y, Tian Q, Wang Q, Pollard J, Srivastava P, et al.
Cell Rep
. 2023 Oct;
42(10):113299.
PMID: 37864794
The current paradigm indicates that naive T cells are primed in secondary lymphoid organs. Here, we present evidence that intranasal administration of peptide antigens appended to nanofibers primes naive CD8...
7.
Al Seesi S, Al-Okaily A, Shcheglova T, Sherafat E, Alqahtani F, Hagymasi A, et al.
J Comput Biol
. 2023 Mar;
30(4):538-551.
PMID: 36999902
High-throughput DNA and RNA sequencing are revolutionizing precision oncology, enabling personalized therapies such as cancer vaccines designed to target tumor-specific neoepitopes generated by somatic mutations expressed in cancer cells. Identification...
8.
Mohapatra A, Srivastava P
Methods Mol Biol
. 2023 Mar;
2618:251-264.
PMID: 36905522
The presentation of peptides derived from exogenous antigens on major histocompatibility complex (MHC) class I molecules of antigen-presenting cells (APCs), termed cross-presentation, is crucial for the activation of cytotoxic T-lymphocytes...
9.
Hagymasi A, Dempsey J, Srivastava P
Curr Protoc
. 2022 Nov;
2(11):e592.
PMID: 36367390
Heat-shock proteins (HSPs), or stress proteins, are abundant and highly conserved, present in all organisms and in all cells. Selected HSPs, also known as chaperones, play crucial roles in folding...
10.
Ebrahimi-Nik H, Moussa M, Englander R, Singhaviranon S, Michaux J, Pak H, et al.
Nat Commun
. 2021 Nov;
12(1):6423.
PMID: 34741035
High-affinity MHC I-peptide interactions are considered essential for immunogenicity. However, some neo-epitopes with low affinity for MHC I have been reported to elicit CD8 T cell dependent tumor rejection in...